Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Targeting S6K1 and S6K2 by siRNA and sgRNA in LN229 GBM cells

ABSTRACT: Targeting S6K1 and S6K2 by siRNA and sgRNA in LN229 GBM cells

PROVIDER: PRJNA805545 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR17983900.fastq.gz	Fastqsanger.gz
	SRR17983901.fastq.gz	Fastqsanger.gz
	SRR17983902.fastq.gz	Fastqsanger.gz
	SRR17983903.fastq.gz	Fastqsanger.gz
	SRR17983904.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 88

Similar Datasets

Targeting S6K1 and S6K2 by siRNA and sgRNA in LN229 GBM cells

Project description:To systematically identify the function of S6K1 and S6K2 in glioblastoma cells, LN229 cells were stably transduced with Cas9, control non-targeting sgRNA (sgNT), or sgRNAs targeting S6K1 or S6K2. The cells were then transiently transfected with non-targeting siRNAs (siNT), or siRNA pools targeting S6K1 or S6K2. RNA sequencing was performed to compare cellular responses to inactivation of single or combination S6 kinases.

2024-08-28 | GSE196591 | GEO

Revealing different roles of the mTOR-targets S6K1 and S6K2 in breast cancer by expression profiling and structural analysis

Project description:Expression profiles of ZR751 breast cancer cells after downregulation of S6K1, S6K2 and S6K1+S6K2.

2015-12-09 | GSE75813 | GEO

Revealing different roles of the mTOR-targets S6K1 and S6K2 in breast cancer by expression profiling and structural analysis

Project description:Expression profiles of ZR751 breast cancer cells after downregulation of S6K1, S6K2 and S6K1+S6K2. Triplicates of control, S6K1siRNA, S6K2siRNA and S6K1+S6K2siRNA, in total twelve samples.

2015-12-09 | E-GEOD-75813 | biostudies-arrayexpress

RNA-seq analysis of gene expression profile in PTEN WT and KO LN229 glioblastoma multiforme (GBM) Xenograft tumor Transcriptomes

Project description:The goal of this study is to compare gene expression profiles of PTEN WT and KO GBM cells when they are growing in vivo. Isogenic PTEN WT or KO LN229 GBM cells were subcutaneously implanted into Balb/c nude mice (two in each group) to form tumor. At the 30th day tumors were harvested and total RNA was isolated. RNA-seq analysis was performed to examine the differential express pattern of the two type of xenografts.

2019-09-04 | GSE136738 | GEO

Transcriptomic analysis of LN229 cell treated by unit of bortezomib and panobinostat

Project description:We report the application of unit of bortezomib and panobinostat on LN229 cell , and further explored the mechanism of drugs on GBM cells.

2022-06-30 | GSE206984 | GEO

S6K2 IS A NOVEL TARGET IN MAPKi-RESISTANT NRAS-MUTANT MELANOMA

Project description:Melanoma is often driven by NRAS mutations. Although oncogenic NRAS activates MAPK signaling, inhibition of this pathway has limited efficacy in NRAS-mutant tumors. As there are limited options to treat these tumors, there is a pressing need to identify NRAS-mutant-specific vulnerabilities that can be therapeutically exploited. Metabolic reprogramming is one of the hallmarks of RAS-mutant tumors, creating a dependency on key metabolic pathways. This dependency could be leveraged to combat these tumors. We discovered that abrogation of S6K2, a mTORC1 effector, triggers accumulation of unsaturated fatty acids, lipid peroxidation and cell death selectively in NRAS-mutant melanoma cells that are resistant to MAPK inhibition. S6K2 depletion induced upregulation of S6K1 and PPAR, triggering apoptotic and ferroptosis-like cell death. Conversely, depletion of S6K1 diminished lipid synthesis and cell proliferation, without eliciting cell death. Collectively, our data indicate that a fine balance between S6K1 and S6K2 activity and metabolic homeostasis is required to prompt cell death of NRAS-mutant melanoma. S6K2 is hence a novel therapeutic target for MAPKi-resistant NRAS-mutant melanoma.

2020-03-06 | GSE127916 | GEO

DNA methylation characterisation of glioblastoma (GBM) cell lines.

Project description:Early passages (< 10) of frequently used GBM cell lines A172, LN18, LN229, T98G, U87-MG, U138-MG and U251-MG were characterised for global DNA methylation patterns.

2023-07-01 | GSE119592 | GEO

Gene expression analysis of glioblastoma (GBM) cell lines.

Project description:Early passages (< 10) of frequently used GBM cell lines A172, LN18, LN229, T98G, U87-MG, U138-MG and U251-MG were characterised for gene expression microarray analysis.

2023-07-01 | GSE119468 | GEO

Genomic copy number number characterisation of glioblastoma (GBM) cell lines.

Project description:Early passages (< 10) of frequently used GBM cell lines A172, LN18, LN229, T98G, U87-MG, U138-MG and U251-MG were characterised for genomic copy number by array CGH.

2023-07-01 | GSE119586 | GEO

S6K_RiBi

Project description:Transcriptional analysis of concequent lack of rpS6 kinase activity in mice livers hepatocytes due to deletion of S6 kinases 1 and 2 (S6K1 and S6K2).

2013-01-16 | E-MEXP-3518 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data